Author

Aditi Gulati

Institute of Cancer ResearchORCID 0000-0001-7476-2524Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Andrew N.J. TuttiD· 1 shared Christopher J. LordiD· 1 shared Dragomir B. KrasteviD· 1 shared Éric Pujade-LauraineiD· 1 shared Feifei SongiD· 1 shared Hui Xiao· 1 shared Isabelle Laure Ray-CoquardiD· 1 shared Lorena Magraner-PardoiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrew N.J. TuttORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintMay 25, 2026

Reversion mutations define minimal BRCA1/2 requirements for therapy resistance

Lorena Magraner-Pardo, William Kerrison, Dragomir B. Krastev…·Christopher J. Lord

The paper identifies BRCA1/2 reversion mutations associated with drug resistance in cancer patients and highlights key domains critical for resistance.

DOI 10.64898/2026.05.22.727163

humanwhole-exome sequencing

𝕏 PostBluesky